Focused on Innovation and Breakthrough Science

Partnering to Support Women and Girls

Women and girls are among the most vulnerable in the world to HIV infection. Here’s how we’re mobilizing to help women and girls fight back.

The search for a vaccine to prevent HIV has been a 30-year quest. For over a decade, we have focused on delivering breakthrough science to stop the transmission of infection—a critical goal if we are to end this epidemic.

We remain dedicated to fulfill our mission of delivering transformational innovations to meet the diverse needs of the HIV community and are excited to be bringing forward an evolved therapy with darunavir as its backbone.

Non-adherence to treatment remains a challenge for many people living with HIV and one of the main drivers of resistance to HIV medicines. Our hope is to make HIV treatment manageable for all by developing innovative solutions like long-acting regimens.

Innovation and Progress Over the Years

Johnson & Johnson and its Janssen Pharmaceutical Companies stand united with the global community to make an HIV-free world a reality.

The Discovery

Scientists discover the virus that causes AIDS.

The World Gathers

The first International AIDS Conference (IAC) takes place.

The Declaration

The World Health Organization declared December 1st to be World AIDS Day.

First Treatment Guidelines Are Issued

The U.S. Centers for Disease Control and Prevention (CDC) issues the first national treatment guidelines for the use of ARV therapy in adults and adolescents.

Region is the World's Epicenter of HIV/AIDS

Approximately 3.5 million new infections occur in Sub-Saharan Africa.

Johnson & Johnson Launches GAPP

In 2006, Johnson and Johnson launched the Global Access and Partnerships Program, a global HIV drug access program.

Janssen Gets Approval in the U.S.

Janssen’s Novel Protease Inhibitor Is Approved in the U.S.

NNRTI Gets the Green Light

Janssen’s non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved in the E.U. and U.S.

Number of People Receiving Treatment for HIV Grows

WHO estimates 5.2 million people receiving treatment for HIV.

Janssen Announces Exciting Agreement

Janssen and IAVI enter into an agreement to develop a preventive HIV vaccine based on Janssen's AdVac® adenovirus vector technology.

Janssen Partners With EGPAF

Janssen partners with The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the Partnership for Supply Chain Management System (PFSCMS) to implement New Horizons Advancing Pediatric HIV Care Collaborative.

A Drug Donation Program

Janssen announces first-of-its kind drug donation program for HIV treatment-experienced children.

A Goal Is Set

UNAIDS sets 90-90-90 goals in a bid to end the AIDS epidemic.

Drugs Become More Affordable

Agreement in 112 countries to manufacture generic versions of Janssen's NNRTI.

Collaborations Continue

Janssen announces expanded collaboration with International Partnership for Microbicides for Development and Commercialization of NNRTI for prevention of sexual transmission of HIV.

A New Study Has Promise

Study published in Science highlights potential of investigational preventive vaccine regimen.

Clinical Trial Phase

International Phase I/IIa clinical trial commences to evaluate safety and immunogenicity of Janssen’s HIV preventive vaccine regimen in healthy, HIV-uninfected volunteers.

A Global Promise

Major new global commitments to end HIV infection in adolescent girls and women announced.

A Step Forward in Developing Countries

License granted for Janssen’s protease inhibitor to be developed and commercialized in a number of developing countries to support HIV prevention in women.

A Call for Global Collaboration

The historic challenge of finding an HIV vaccine requires global collaboration.





















This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.